ARTIFICIAL INTELLIGENCE FOR NEW DRUG DESIGN
We have proven our success
The Cancerappy Platform has generated all the drug programs in our portfolio, focusing both on the validation of new targets and on groups of compounds such as PROTACs and nanotechnology, in close collaboration with innovative academic centers.
CancerAppy is a biotech specialized in the field of cancer research, focused on the discovery and development of new therapeutic targets, based on its own artificial intelligence methodology
We have developed solutions that allow us to be more efficient and precise in the discovery of small molecules.
We work in the early stage of the Drug Discovery Value Chain.
From the initial analysis of the Target to the preclinical phase
Thanks to our deep knowledge and expertise in oncology and AI, we use a massive amount of multimodal data in our state-of-the-art AI algorithms, helping to identify new therapeutic targets, identify lead compounds, and determine the mechanism of action of a given compound. as well as possible drug combinations.
We would be happy to talk to you.
Latest news about CancerAppy…
CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload...
CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common...
We are delighted to announce our first collaborative scientific research article. At CancerAppy, our commitment to harnessing the power of AI in...